N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl-1H-indazol-5-yl]oxy}propan-1-amine compound, process for preparing it and pharmaceutical composition comprising thereof

Abstract

The present invention relates to a compound of formula I: wherein X is O, S, NR, CH2, CH2, Y, CH2 Z, CO, CONR or NRCO; Y is O, S or NR; Z is CO; n is O or an integer of 1, 2, 3, 4, 5 or 6 when X is CH2; n is an integer of 1,2,3,4,5 or 6 when X is CH2Z, CO or NRCO; n is an integer of 2,3,4,5 or 6 when X is 0, S, NR, CH2 Y or CONR; R is H or an optionally substituted alkyl group; R1 is H or an alkyl, cycloalkyl, aryl or heteroaryl group each optionally substituted; R2 is an optionally substituted alkyl, cycloalkyl, aryl or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S; R3 and R4 are each independently H, or an optionally substituted alkyl group; R5 and R6 are each independently H, or an alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted, or R5 and R6 may be taken together with the atom to which they are attached to form an optionally substituted 3- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S; R7 is halogen, CN, OR8, CO2 R9, CONR10 R11, or an alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; m is an integer of 0, 1, 2, or 3; R8 is H, COR12 or an alkyl alkenyl, alkynyl, aryl or heteroaryl group each optionally substituted; R9 is H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted; R10 and R11 are each independently H or an optionally substituted alkyl group; and R12 is an optionally substituted C1-C6alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group; or a stereoisomer thereof. And process for preparing the compound and pharmaceutical composition comprising thereof This compound is useful for treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.